Lapaquistat Acetate

Summary

Lapaquistat Acetate (CHEMBL435224) is a phase-3 clinical-stage small molecule; indicated across 4 conditions including type 2 diabetes mellitus and hyperlipidemia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 4 conditions
• Clinical trials: 16
• Chemistry: 645.1 Da · C33H41ClN2O9

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL435224
Name	Lapaquistat Acetate
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	9874248
Molecular formula	C33H41ClN2O9
Molecular weight	645.1
InChIKey	CMLUGNQVANVZHY-POURPWNDSA-N

SMILES: CC(=O)OCC(C)(C)CN1C2=C(C=C(C=C2)Cl)[C@H](O[C@@H](C1=O)CC(=O)N3CCC(CC3)CC(=O)O)C4=C(C(=CC=C4)OC)OC

IUPAC name: 2-[1-[2-[(3R,5S)-1-(3-acetyloxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-5H-4,1-benzoxazepin-3-yl]acetyl]piperidin-4-yl]acetic acid

Also known as: Lapaquistat acetate, TAK 475, TAK-475, TAK475, LAPAQUISTAT ACETATE

Patent coverage: 337 distinct patent families (959 SureChEMBL compound mentions), from 4 matched compound structure(s). One matched structure accounts for 631 (66%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Squalene synthase, Squalene synthase.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
FDFT1	7.11	IC50	78	nM	CHEMBL_ACT_1120535
Q02769	7.11	IC50	78	nM	CHEMBL_ACT_18880856
FDFT1	6.67	IC50	213	nM	CHEMBL_ACT_6204612

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
type 2 diabetes mellitus	3	MONDO:0005148	MONDO:0005148
hyperlipidemia	2	MONDO:0021187	MONDO:0021187

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 16.

Phase distribution

Phase	Trials
PHASE3	13
PHASE2	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00143663	PHASE3	COMPLETED	Effect of Lapaquistat Acetate on Blood Cholesterol Levels in Subjects With Elevated Cholesterol
NCT00143676	PHASE3	COMPLETED	Efficacy of Lapaquistat Acetate and Atorvastatin on Blood Cholesterol Levels in Subjects With Primary Hypercholesterolemia
NCT00249899	PHASE3	TERMINATED	Efficacy of Lapaquistat Acetate Alone or Combined With High-Dose Statin Therapy in Subjects With Hypercholesterolemia
NCT00249912	PHASE3	COMPLETED	Efficacy of Lapaquistat Acetate Alone or Combined With Rosuvastatin in Subjects With Hypercholesterolemia
NCT00251680	PHASE3	COMPLETED	Efficacy of Lapaquistat Acetate in Subjects Currently Treated With Lipid-Lowering Therapy.
NCT00256178	PHASE3	COMPLETED	Efficacy of Lapaquistat Acetate and Simvastatin in Subjects With Primary Dyslipidemia.
NCT00263081	PHASE3	TERMINATED	Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Treatment on Blood Cholesterol Levels in Subjects With Homozygous Familial Hypercholesterolemia
NCT00268697	PHASE3	COMPLETED	Efficacy of Lapaquistat Acetate Alone and With Ezetimibe in Subjects With Primary Dyslipidemia.
NCT00286481	PHASE3	COMPLETED	Efficacy of Lapaquistat Acetate Alone or Combined With Simvastatin in Subjects With Hypercholesterolemia
NCT00487994	PHASE3	COMPLETED	Safety and Efficacy of Lapaquistat Acetate Taken Alone and With Atorvastatin in Subjects With Primary Dyslipidemia
NCT00532311	PHASE3	TERMINATED	Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia
NCT00532558	PHASE3	TERMINATED	Efficacy of Lapaquistat Acetate on Blood Cholesterol Levels in Treating Subjects With Hypercholesterolemia
NCT00868127	PHASE3	COMPLETED	Safety of Lapaquistat Acetate in Subjects With Hypercholesterolemia
NCT00813527	PHASE2	COMPLETED	Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels
NCT00864643	PHASE2	COMPLETED	Efficacy and Safety of Lapaquistat Acetate Coadministered With Atorvastatin in Subjects With Hypercholesterolemia
NCT00865228	PHASE2	TERMINATED	Efficacy of Lapaquistat Acetate in Subjects With Hypercholesterolemia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).